The Lancet. Published Online December 22, 2016 http://dx.doi.org/10.1016/S0140-6736(16)32621-6. Open Access
Available in English, French, Portuguese and Arabic
Successful immunization of a critical mass of the African population with one or several safe and efficacious COVID-19 vaccines.Key objectives1. Accelerate African involvement in the clinical development of a vaccine. 2. Ensur...e African countries can access a sufficient share of the global vaccine supply.3. Remove barriers to widespread delivery and uptake of effective vaccines across Africa.
more
Guidance for addressing a global infodemic and fostering demand for immunization
December 2020
Misinformation threatens the success of vaccination programs across the world. This guide aims to help organizations to address the global infodemic through the development of strategic and well-coordina...ted national action plans to rapidly counter vaccine misinformation and build demand for vaccination that are informed by social listening.
more
This catalogue provides tools and information resources to support EU/EEA countries in addressing the challenging issue of vaccine hesitancy. The catalogue provides examples of practices that can serve as a resource for other countries. The project was developed in the context of ECDC’s support fo...r EU/EEA Member States in prevention and control of vaccine-preventable diseases, including effective communication to promote immunisation.
more
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
Initial public health responses to control the pandemic focused on promoting protective behaviors among the general population, including frequent hand washing, physical distancing and the use of face masks in public spaces However, many saw these only as interim measures to reduce the spread of the... virus and hopes for a return to a sense of ‘ rested on the development of a safe and effective vaccine.
more
These are standing orders for eligible nurses and healthcare professionals to administer the Moderna COVID-19 vaccine to persons 18 years of age and older
7 June 2021
The Africa Regulatory Taskforce is a joint effort established by the Africa Centres for Disease Control and Prevention (Africa CDC), the African Union Development Agency (AUDA-NEPAD) coordinated African Medicines Regulatory Harmonization (AMRH) Initiative, and the World Health Organisat...ion’s (WHO) African Vaccine Regulatory Forum (AVAREF) to enable and provide support for an effective regulatory framework for COVID-19 Vaccines in Africa.
more
24 September 2021. The vaccine has been authorized by the Chinese National Regulatory Authority (NRA) – the National Medicinal Product Administration (NMPA) – as well as other regulatory authorities. Because WHO has granted Emergency Use Listing (EUL) for the COVID-19 Vaccine BIBP/ Sinopharm, th...e Africa Union and Africa CDC’s Regulatory Taskforce has endorsed the Emergency Use Authorization for the vaccine (see scenario #1) and the specification is 0.5ml/dose, 1 dose/vial; or 2 doses/vial; or 5 doses/vial. As such, African Union Member States are recommended to waive any review processes and rely directly on the WHO EUL via the AVAREF managed pathway described in Scenario #1.
more
24 September 2021. The vaccine has been authorized by the Chinese National Regulatory Authority (NRA) – the National Medicinal Product Administration (NMPA) – as well as other regulatory authorities. Because WHO has granted Emergency Use Listing (EUL) for the Sinovac COVID-19 vaccine (Vero Cell ...[Inactivated]) – CoronaVac, the Africa Union and Africa CDC’s Regulatory Taskforce has endorsed the Emergency Use Authorisation for the vaccine (see scenario #1). As such, African Union Member States are recommended to waive any review processes and rely directly on the WHO EUL via the AVAREF managed pathway described in Scenario #1
more
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been ...updated: version 15 March 2022.
The vaccine is formulated from an inactivated SARS-CoV-2 antigen and is presented in single dose vials and multidose vials of 5, 10 and 20 doses.
more
The pandemic has emphasized the high risk of avoidable harm to patients, health workers, and the general public, and has identified a range of safety gaps across all core components of health systems at all levels.
The rapid review ‘Implications of the COVID-19 pandemic for patient safety’ ex...plores impacts that the COVID-19 pandemic did have on patient safety in terms of risks and avoidable harm, specifically in terms of diagnostic, treatment and care management related issues as well as highlights the main patterns of these implications within the broader health system context.
more